Teva Pharmaceutical's supplemental new drug application for the combined use of Trisenox, or arsenic trioxide, with retinoic acid for the induction of remission and consolidation in patients with newly diagnosed low- to intermediate-risk acute promyelocytic leukemia whose APL is characterized by the t(15;17) translocation genetic profile, was accepted by the FDA for priority review. The drug is approved for patients with acute APL who are refractory to, or relapsed from, retinoid and anthracycline chemotherapy and whose APL has the same genetic profile cited in the supplemental NDA.
Teva's application for expanded use of APL drug granted priority review
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.